175 related articles for article (PubMed ID: 69827)
1. Hyperprolactinaemia and antihypertensive effect of bromocriptine in essential hypertension. Identification of abnormal central dopamine control.
Stumpe KO; Kolloch R; Higuchi M; Krück F; Vetter H
Lancet; 1977 Jul; 2(8031):211-4. PubMed ID: 69827
[TBL] [Abstract][Full Text] [Related]
2. [Raised plasma-prolactin levels in essential hypertension: index of reduced hypothalamic dopaminergic activity (author's transl)].
Kolloch R; Stumpe KO; Higuchi M; Vetter H; Krück F
Klin Wochenschr; 1977 Oct; 55(20):1013-8. PubMed ID: 926711
[TBL] [Abstract][Full Text] [Related]
3. [Hemodynamic and biological effects of bromocriptine in essential hypertension].
Allain H; Daubert JC; Massart C; van den Driessche J; Gouffault J
Arch Mal Coeur Vaiss; 1982 Sep; 75(9):951-62. PubMed ID: 6816179
[TBL] [Abstract][Full Text] [Related]
4. [Features of dopaminergic system function in menopausal females with arterial hypertension].
Ustinova SE; Iarnykh EV; Masenko VP; Arabidze GG
Ter Arkh; 2000; 72(1):35-40. PubMed ID: 10687204
[TBL] [Abstract][Full Text] [Related]
5. [Effect of bromocriptine on arterial blood pressure and serum prolactin level in patients with essential arterial hypertension].
Hudziak G; Kuska J
Kardiol Pol; 1988; 31 Suppl 1():22-9. PubMed ID: 3221620
[No Abstract] [Full Text] [Related]
6. Hyperprolactinaemia and antihypertensive effect of bromocriptine in essential hypertension.
Lewis MJ; Henderson AH
Lancet; 1977 Sep; 2(8037):562. PubMed ID: 95768
[No Abstract] [Full Text] [Related]
7. Dopaminergic control of prolactin and blood pressure: altered control in essential hypertension.
Sowers JR; Nyby M; Jasberg K
Hypertension; 1982; 4(3):431-7. PubMed ID: 7068198
[No Abstract] [Full Text] [Related]
8. Enhanced depressor effect of bromocriptine in the DOCA/NaCl hypertensive rat.
Nagahama S; Chen YF; Oparil S
Am J Physiol; 1985 Jul; 249(1 Pt 2):H64-70. PubMed ID: 2861750
[TBL] [Abstract][Full Text] [Related]
9. Is normoreninemic essential hypertension caused by disordered central dopaminergic regulation?
Ogihara T; Maruyama A; Naka T; Higaki J; Kanda T; Goto M; Onishi T; Kumahara Y
Clin Exp Hypertens (1978); 1980; 2(1):89-97. PubMed ID: 6774864
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the plasma-aldosterone response to frusemide by bromocriptine.
Edwards CR; Miall PA; Hanker JP; Thorner MO; Al-Dujaili EA; Besser GM
Lancet; 1975 Nov; 2(7941):903-5. PubMed ID: 53377
[TBL] [Abstract][Full Text] [Related]
11. Effect of bromocriptine treatment on prolactin, noradrenaline and blood pressure in hypertensive haemodialysis patients.
Degli Esposti E; Sturani A; Santoro A; Zuccalà A; Chiarini C; Zucchelli P
Clin Sci (Lond); 1985 Jul; 69(1):51-6. PubMed ID: 3905210
[TBL] [Abstract][Full Text] [Related]
12. Metoclopramide and domperidone block the antihypertensive effect of bromocriptine in hypertensive patients.
Luchsinger A; Grilli M; Velasco M
Am J Ther; 1998 Mar; 5(2):81-8. PubMed ID: 10099042
[TBL] [Abstract][Full Text] [Related]
13. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
Krysiak R; Okopien B
Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):251-6. PubMed ID: 25123447
[TBL] [Abstract][Full Text] [Related]
14. Metoclopramide blocks bromocriptine induced antihypertensive effect in hypertensive patients.
Luchsinger A; Grilli M; Forte P; Morales E; Velasco M
Int J Clin Pharmacol Ther; 1995 Sep; 33(9):509-12. PubMed ID: 8520809
[TBL] [Abstract][Full Text] [Related]
15. Prolactin, bromocriptine and dopaminergic neurotransmission.
Lamberts SW; Birkenhäger JC
Neth J Med; 1976; 19(3):113-7. PubMed ID: 6921
[No Abstract] [Full Text] [Related]
16. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
Rains CP; Bryson HM; Fitton A
Drugs; 1995 Feb; 49(2):255-79. PubMed ID: 7729332
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular effects of bromocriptine and lergotrile in renal and spontaneously hypertensive rats.
Tadepalli AS; Novak PJ
Arch Int Pharmacodyn Ther; 1983 Nov; 266(1):93-105. PubMed ID: 6141774
[TBL] [Abstract][Full Text] [Related]
18. Dopaminergic effects on kidney function and responsiveness of aldosterone, plasma renin activity, prolactin, catecholamines, and blood pressure to stimulation in patients with prolactinoma. Comparison of the efficacy of pergolide and bromocriptine therapy.
Jungmann E; Haak T; Althoff PH; Fassbinder W; Schöffling K
Arzneimittelforschung; 1988 Feb; 38(2):296-300. PubMed ID: 3285838
[TBL] [Abstract][Full Text] [Related]
19. Effects of bromocriptine on responses to stress in spontaneously hypertensive rats.
Sowers JR
Hypertension; 1981; 3(5):544-50. PubMed ID: 7028608
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of the depressor effect of bromocriptine in the spontaneously hypertensive rat.
Nagahama S; Chen YF; Oparil S
J Pharmacol Exp Ther; 1984 Feb; 228(2):370-5. PubMed ID: 6363675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
